Published in Cancer Res on January 01, 2008
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A (2010) 1.30
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
Calpain-mediated proteolysis of paxillin negatively regulates focal adhesion dynamics and cell migration. J Biol Chem (2011) 1.23
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest (2012) 1.09
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol (2010) 1.08
MET pathway as a therapeutic target. J Thorac Oncol (2009) 1.06
Paxillin mediates sensing of physical cues and regulates directional cell motility by controlling lamellipodia positioning. PLoS One (2011) 1.06
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol (2009) 1.01
MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr (2010) 1.00
Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol (2009) 1.00
c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. Genes Cancer (2013) 0.98
Diverse roles for the paxillin family of proteins in cancer. Genes Cancer (2012) 0.98
The MET axis as a therapeutic target. Update Cancer Ther (2009) 0.98
p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase. Cancer Res (2011) 0.96
Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma. PLoS One (2012) 0.93
Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Transl Med (2013) 0.92
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One (2014) 0.89
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther (2013) 0.89
CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells. PLoS One (2013) 0.89
Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol. J Proteome Res (2010) 0.88
Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression. J Cell Sci (2014) 0.87
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma (2011) 0.86
MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. Int J Clin Exp Pathol (2015) 0.85
Emerging role of paxillin-PKL in regulation of cell adhesion, polarity and migration. Cell Adh Migr (2010) 0.83
Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Cell Death Differ (2014) 0.83
Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic value. Int J Clin Exp Pathol (2015) 0.81
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer (2014) 0.81
Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med (2015) 0.81
Expression of Paxillin is Correlated with Clinical Prognosis in Colorectal Cancer Patients. Med Sci Monit (2015) 0.81
HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma. PLoS One (2015) 0.81
Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med (2010) 0.80
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn (2016) 0.80
FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget (2016) 0.78
Paxillin expression is closely linked to the pathogenesis, progression and prognosis of gastric carcinomas. Oncol Lett (2013) 0.78
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One (2014) 0.77
Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87. Oncotarget (2015) 0.77
MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications. Transl Lung Cancer Res (2012) 0.76
Paxillin: a crossroad in pathological cell migration. J Hematol Oncol (2017) 0.75
Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies. J Transl Med (2017) 0.75
Mitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now? Biomark Med (2017) 0.75
Evaluation of paxillin expression in patients with oral squamous cell carcinoma: An immunohistochemical study. J Oral Maxillofac Pathol (2017) 0.75
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol (2006) 8.52
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
p21-activated kinases in cancer. Nat Rev Cancer (2006) 4.24
Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol (1989) 4.20
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res (2006) 2.86
The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol (2002) 2.73
Paxillin interactions. J Cell Sci (2000) 2.67
Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. J Cell Biol (1996) 2.63
The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci U S A (1997) 2.00
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat (2005) 1.94
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86
Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell (2004) 1.86
Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol (2004) 1.83
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Localized suppression of RhoA activity by Tyr31/118-phosphorylated paxillin in cell adhesion and migration. J Cell Biol (2002) 1.78
Characterization of the TGF beta 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem (1994) 1.76
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer (2006) 1.56
Molecular abnormalities in lung cancer. J Clin Oncol (1998) 1.52
Genetic alterations in cancer knowledge system: analysis of gene mutations in mouse and human liver and lung tumors. Toxicol Sci (2006) 1.43
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene (1999) 1.39
Lung carcinoma in African Americans. Nat Clin Pract Oncol (2007) 1.33
Regulation of paxillin family members during epithelial-mesenchymal transformation: a putative role for paxillin delta. J Cell Sci (2005) 1.31
Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res (2004) 1.27
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem (1997) 1.27
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene (1995) 1.23
Monocyte cells and cancer cells express novel paxillin isoforms with different binding properties to focal adhesion proteins. J Biol Chem (1997) 1.10
CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem (1995) 1.06
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.03
Interaction of bcl-2 with Paxillin through its BH4 domain is important during ureteric bud branching. J Biol Chem (2003) 1.01
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer (2006) 1.01
Gene expression profiles in human non-small and small-cell lung cancers. Eur J Cancer (2003) 0.96
Soluble collagen VI induces tyrosine phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase erk2 in fibroblasts. Exp Cell Res (1999) 0.95
Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. J Bone Miner Res (2003) 0.92
Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung. Cancer Sci (2005) 0.92
Focal adhesion kinase, paxillin, and bcl-2: analysis of expression, phosphorylation, and association during morphogenesis. Dev Dyn (1999) 0.91
Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction. Environ Health Perspect (1992) 0.87
Lung cancer: an ever increasing store of in-depth basic knowledge and the beginning of its clinical application. Oncogene (2002) 0.80
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Recent segmental duplications in the human genome. Science (2002) 21.30
Segmental duplications and copy-number variation in the human genome. Am J Hum Genet (2005) 13.33
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med (2008) 10.88
Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet (2006) 10.36
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am J Hum Genet (2006) 7.70
Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet (2009) 7.07
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell (2007) 5.09
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A (2008) 4.75
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Transgenic mice with green fluorescent protein-labeled pancreatic beta -cells. Am J Physiol Endocrinol Metab (2002) 4.45
Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med (2005) 4.31
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res (2002) 3.90
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol (2013) 3.67
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. Pediatrics (2004) 3.48
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc (2010) 3.44
Prader-Willi syndrome. Genet Med (2011) 3.40
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst (2003) 3.09
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol (2004) 3.08
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol (2008) 3.02
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med (2005) 2.91
Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet (2011) 2.85
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J (2009) 2.82
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
The structure and evolution of centromeric transition regions within the human genome. Nature (2004) 2.78
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol (2009) 2.66
EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell (2013) 2.63
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Covariation of synaptonemal complex length and mammalian meiotic exchange rates. Science (2002) 2.54
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg (2004) 2.53
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol (2004) 2.51
Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging. J Am Coll Cardiol (2004) 2.50
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol (2003) 2.45
Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis (2008) 2.41
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol (2008) 2.40
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36